Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …